Sangeeta Kumari

Sangeeta got her PhD from NCCS, Pune (India) where she studied host pathogen interactions. She moved to Finland for her postdoc where she joined Prof. Sirpa Jalkanen lab in Turku University and studied the role of Stabilin-1 molecule in Acute myeloid leukemia. Continuing her research in the Netherlands, she worked in the laboratory of Dr. Jeanette Leusen at the UMC Utrecht, where she developed expertise in antibody related work. She has a keen interest to pursue her career in the development of therapeutic antibodies and joined the Citryll team in October 2019. She is part of the mechanism of action team (MoA) which is focused on unravelling the working mechanism of Citryll’s lead antibody drug candidate CIT-013 and identifying its new therapeutic strategies applications.